Heterogeneity and clonal evolution of acquired PARP inhibitor resistance in TP53- and BRCA1-deficient cells.

Homologous recombination (HR)-deficient cancers are sensitive to inhibitors of Poly-ADP Ribose Polymerase (PARPi), which have shown clinical efficacy in the treatment of high-grade serous cancers (HGSC). However, the majority of patients will relapse, and acquired PARPi resistance is emerging as a p...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Res
Asıl Yazarlar: Färkkilä, Anniina, Rodríguez, Alfredo, Oikkonen, Jaana, Gulhan, Doga C., Nguyen, Huy, Domínguez, Julieta, Ramos, Sandra, Mills, Caitlin E., Pérez-Villatoro, Fernando, Lazaro, Jean-Bernard, Zhou, Jia, Clairmont, Connor S., Moreau, Lisa A., Park, Peter J., Sorger, Peter K., Hautaniemi, Sampsa, Frias, Sara, D’Andrea, Alan D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8323804/
https://ncbi.nlm.nih.gov/pubmed/33514515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-2912
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller